| Title |
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
|
|---|---|
| Published in |
Cancer Discovery, February 2021
|
| DOI | 10.1158/2159-8290.cd-20-1465 |
| Pubmed ID | |
| Authors |
Vinod A Pullarkat, Norman J Lacayo, Elias Jabbour, Jeffrey E Rubnitz, Ashish Bajel, Theodore W Laetsch, Jessica Leonard, Susan I Colace, Seong Lin Khaw, Shaun A Fleming, Ryan J Mattison, Robin Norris, Joseph T Opferman, Kathryn G Roberts, Yaqi Zhao, Chunxu Qu, Mohamed Badawi, Michelle Schmidt, Bo Tong, John C Pesko, Yan Sun, Jeremy A Ross, Deeksha Vishwamitra, Lindsey Rosenwinkel, Su Young Kim, Amanda Jacobson, Charles G Mullighan, Thomas B Alexander, Wendy Stock |
X Demographics
The data shown below were collected from the profiles of 30 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 12 | 40% |
| United Kingdom | 2 | 7% |
| Algeria | 1 | 3% |
| Belgium | 1 | 3% |
| Finland | 1 | 3% |
| Unknown | 13 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 53% |
| Scientists | 10 | 33% |
| Science communicators (journalists, bloggers, editors) | 3 | 10% |
| Practitioners (doctors, other healthcare professionals) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 142 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 142 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 11% |
| Student > Ph. D. Student | 14 | 10% |
| Student > Postgraduate | 7 | 5% |
| Student > Master | 7 | 5% |
| Student > Bachelor | 7 | 5% |
| Other | 21 | 15% |
| Unknown | 70 | 49% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 23% |
| Biochemistry, Genetics and Molecular Biology | 17 | 12% |
| Immunology and Microbiology | 7 | 5% |
| Unspecified | 4 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 1% |
| Other | 6 | 4% |
| Unknown | 73 | 51% |
Attention Score in Context
This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 February 2024.
All research outputs
#1,119,171
of 25,837,817 outputs
Outputs from Cancer Discovery
#577
of 4,151 outputs
Outputs of similar age
#31,445
of 458,852 outputs
Outputs of similar age from Cancer Discovery
#49
of 198 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,151 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 458,852 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 198 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.